David Lovejoy - Protagenic Therapeutics Scientific Officer
| PTIXW Stock | USD 0.01 0 11.11% |
Insider
David Lovejoy is Scientific Officer of Protagenic Therapeutics
| Address | 149 Fifth Avenue, New York, NY, United States, 10010 |
| Phone | 212 994 8200 |
| Web | https://www.protagenic.com |
Protagenic Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9017) % which means that it has lost $0.9017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0636) %, meaning that it generated substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to climb to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Intangible Assets is likely to climb to about 6.4 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.2 K in 2024.Protagenic Therapeutics has accumulated 655.25 K in total debt. Protagenic Therapeutics has a current ratio of 1.31, which is within standard range for the sector. Note, when we think about Protagenic Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Bradley JD | Lumos Pharma | 45 | |
| BBA CPA | Lumos Pharma | 57 | |
| Jeff York | Seres Therapeutics | N/A | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| MD BA | Lumos Pharma | 69 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| David MBA | Seres Therapeutics | 63 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 |
Protagenic Therapeutics Leadership Team
Elected by the shareholders, the Protagenic Therapeutics' board of directors comprises two types of representatives: Protagenic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagenic. The board's role is to monitor Protagenic Therapeutics' management team and ensure that shareholders' interests are well served. Protagenic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagenic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Director | ||
| Robert Stein, Chief Director | ||
| CFA MD, CFO Sec | ||
| Garo Armen, CoFounder Chairman | ||
| MD CFA, CFO Secretary | ||
| David Lovejoy, Scientific Officer | ||
| Andrew Slee, Chief Officer |
Protagenic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagenic Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.9 | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 671.09 K | ||||
| Cash Per Share | 0.06 X | ||||
| Total Debt | 655.25 K | ||||
| Current Ratio | 1.34 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.